Table 3 Comparison of the key reported outcomes between the antiplatelet drugs, dual antiplatelet therapy and triple anti-thrombotic therapies
Drugs | Death [n (%)] | Life threatening [n (%)] | Hospitalization [n (%)] | Statistical significance |
|---|---|---|---|---|
ASA | 480 (15.5) | 230 (7.4) | 1843 (59.5) | χ2: 94.8; df: 14; p < 0.0001 |
Clopidogrel | 1538 (11.1) | 1059 (8.2) | 6446 (50) | |
ASA and Clopidogrel | 673 (17.6) | 383 (10) | 2209 (57.8) | |
ASA, Clopidogrel and Acenocoumarol | None | 1 (4.5) | 15 (68.2) | |
ASA, Clopidogrel and Apixaban | 6 (4.3) | 13 (9.3) | 29 (20.7) | |
ASA, Clopidogrel and Dabigatran | 32 (18.8) | 6 (3.5) | 86 (50.6) | |
ASA, Clopidogrel and Rivaroxaban | 63 (21.1) | 8 (2.7) | 206 (68.9) | |
ASA, Clopidogrel and Warfarin | 56 (7.1) | 19 (2.4) | 255 (32.5) |